US23954D1090 - Common Stock
Day One Biopharmaceuticals reported a Q4 net loss of $54.5 million and ended 2023 with $366.3 million in cash, ensuring financial stability until 2026.
PDUFA target action date for tovorafenib NDA in relapsed or progressive pLGG remains set for April 30, 2024 Phase 2 FIREFLY-1 tovorafenib registrational...
BRISBANE, Calif., Dec. 19, 2023 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN) (“Day One” or the “Company”), a clinical-stage...
Data subsets to be shared today in plenary oral presentations at the 2023 Society for Neuro-Oncology Annual Meeting
Data subsets to be shared today in plenary oral presentations at the 2023 Society for Neuro-Oncology Annual Meeting...
Day One stock surged 20% on news that the FDA had accepted its New Drug Application for tovorafenib and doesn't plan to hold an advisory committee meeting on the drug. Read more.
Priority review granted with PDUFA target action date of April 30, 2024
The FDA has granted priority review and assigned a Prescription Drug User Fee Act (PDUFA) target action date of April 30, 2024. ...
Day One Biopharmaceuticals (DAWN) disclosed in a Securities and Exchange Filing on Thursday a prospectus for a mixed shelf offering, size undisclosed. Under the offering, the company...
Overall response rate (ORR) greater than 50% across three assessment criteria Median duration of tovorafenib treatment of 15.8 months as of June 5, 2023,...
Overall response rate (ORR) greater than 50% across three assessment criteria Median duration of tovorafenib treatment of 15.8 months as of June 5, 2023,...
Results from FIREFLY-1 demonstrate overall response rate (ORR) of 67% and clinical benefit rate (CBR) of 93% in 69 heavily pretreated Response Assessment...
BRISBANE, Calif., June 12, 2023 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated...
The Nasdaq held near 52-week highs while small caps ramped up.